Landa K, Schmitz R, Farrow NE, et al. - In resectable pancreatic cancer, a superior long-term survival is conferred by surgical resection (SR) than multiagent chemotherapy (MCT).

• This study included patients from the NCDB (2013-2015) with stage I-IIb pancreatic head adenocarcinoma who received either MCT or SR [3,103 patients underwent MCT alone (60.3%) and 2,043 received SR alone (39.7%)].

• SR was shown to have an overall survival (OS) disadvantage at 30 (HR 3.99) and 60 days (HR 1.85), but an OS benefit following 90 days (HR 0.59).

• A landmark analysis conditioned on 90 days survival after treatment commencement revealed improved median OS for SR (17.0 vs 12.2 months); 3-year OS improved by 21.3% with SR, despite older age of patients (median 72 vs 67 years) and higher Charlson-Deyo comorbidity scores (≥2: 11.2 vs 8.6%).